Moreover, as shown in other human cancer types [27], further study combining EZH2-inhibitors with other treatments, such as immunotherapy or targeted therapies in chordomas, should also be considered to improve the outcome of chordoma patients. The gene discussed is EZH2; the disease is chordoma.